The aim of this article is to investigate the phenotype and etiology of prolactinoma-associated headache as well as present and discuss the plausible pain-relieving effect of dopamine agonist treatment.
Methods
In this case-based audit we included 11 patients with prolactinomas and one patient with idiopathic hyperprolactinemia presenting with headache that subsequently improved or resolved after dopamine agonist treatment.
Results
A significant ipsilateral location of tumor mass and reported headache symptoms was observed (p = 0.018). After dopamine agonist treatment seven out of 12 patients became pain free within 2.5 months; after one year of treatment 11 out of 12 reported headache improvement or resolution. Average tumor volume reduction after treatment was 47 ± 22% during 9.5 ± 8.4 months of follow-up. There was no significant association between headache relief and tumor shrinkage (p = 0.43) or normalization of serum prolactin (p = 1.00), respectively.
Conclusions
1) The significant association between lateralization of tumor and headache suggests a mechanical origin of the headache, 2) headache responded to dopamine agonist treatment in most patients, and 3) our observations encourage future prospective controlled trials to investigate the role of hyperprolactinemia in the pathogenesis of headache as well as the therapeutic effects of dopamine agonists.
LevyMJMatharuMSMeeranK. The clinical characteristics of headache in patients with pituitary tumours. Brain2005; 128(Pt 8): 1921–1930.
2.
AbeTMatsumotoKKuwazawaJ. Headache associated with pituitary adenomas. Headache1998; 38: 782–786.
3.
HartmanNVoronSCHershmanJM. Resolution of migraine following bromocriptine treatment of a prolactinoma (pituitary microadenoma). Headache1995; 35: 430–431.
4.
GabrielliMGasbarriniAFioreG. Resolution of migraine with aura after successful treatment of a pituitary microadenoma. Cephalalgia2002; 22: 149–150.
5.
BoscoDBelfioreAFavaA. Relationship between high prolactine levels and migraine attacks in patients with microprolactinoma. J Headache Pain2008; 9: 103–107.
6.
FavierIvan VlietJARoonKI. Trigeminal autonomic cephalgias due to structural lesions: A review of 31 cases. Arch Neurol2007; 64: 25–31.
7.
NegoroKKawaiMTadaY. A case of postprandial cluster-like headache with prolactinoma: Dramatic response to cabergoline. Headache2005; 45: 604–606.
8.
Porta-EtessamJRamos-CarrascoABerbel-GarcíaA. Clusterlike headache as first manifestation of a prolactinoma. Headache2001; 41: 723–725.
9.
GreveEMaiJ. Cluster headache-like headaches: A symptomatic feature? A report of three patients with intracranial pathologic findings. Cephalalgia1988; 8: 79–82.
10.
SarovMValadeDJublancC. Chronic paroxysmal hemicrania in a patient with a macroprolactinoma. Cephalalgia2006; 26: 738–741.
MassiouHLaunayJMLevyC. SUNCT syndrome in two patients with prolactinomas and bromocriptine-induced attacks. Neurology2002; 58: 1698–1699.
13.
LevyMJMatharuMSGoadsbyPJ. Prolactinomas, dopamine agonists and headache: Two case reports. Eur J Neurol2003; 10: 169–173.
14.
ChitsantikulPBeckerWJ. SUNCT, SUNA and pituitary tumors: Clinical characteristics and treatment. Cephalalgia2013; 33: 160–170–160–170.
15.
LevyMJJagerHRPowellM. Pituitary volume and headache: Size is not everything. Arch Neurol2004; 61: 721–725.
16.
LevyMJ. The association of pituitary tumors and headache. Curr Neurol Neurosci Rep2011; 11: 164–170.
17.
ArafahBMPruntyDYbarraJ. The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab2000; 85: 1789–1793.
18.
LevyMJClasseyJDManeesriS. The association between calcitonin gene-related peptide (CGRP), substance P and headache in pituitary tumours. Pituitary2004; 7: 67–71.
19.
LevyMJClasseyJDManeesriS. The relationship between neuropeptide Y expression and headache in pituitary tumours. Eur J Neurol2006; 13: 125–129.
20.
NathooSClasseyJDLevyMJ. Pituitary adenylate cyclase activating protein (PACAP) expressed in pituitary tumours does not account for headache: A clinical-pathological correlation. Cephalalgia2004; 24: 1101–1101.
21.
NathooSClasseyJDLevyMJ. No relationship between vasoactive intestinal polypeptide expression and headache in pituitary tumours. Acta Neurol Scand2005; 111: 317–322.
KingLWMolitchMEGittingerJW Jr. Cavernous sinus syndrome due to prolactinoma: Resolution with bromocriptine. Surg Neurol1983; 19: 280–284.
24.
Olesen J and Dodick DW. The history and examination of headache. In: Olesen J, Goadsby PJ, Ramadan NM, et al. (eds) The headaches, 3rd edn. Philadelphia, USA: Lippincott Williams & Wilkins, 2006.
25.
LiptonRB. How useful is the HIT-6 for measuring headache-related disability?Nat Clin Pract Neurol2006; 2: 70–71.
26.
Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia2004; 24: 1–160.
27.
LundinPPedersenF. Volume of pituitary macroadenomas: Assessment by MRI. J Comput Assist Tomogr1992; 16: 519–528.
LeoneMCuroneMMeaE. Cluster-tic syndrome resolved by removal of pituitary adenoma: The first case. Cephalalgia2004; 24: 1088–1089.
30.
Jiménez CaballeroPE. SUNCT syndrome in a patient with prolactinoma and cabergoline-induced attacks. Cephalalgia2007; 27: 76–78.
31.
LerouxESchwedtTJBlackDF. Intractable SUNCT cured after resection of a pituitary microadenoma. Can J Neurol Sci2006; 33: 411–413.
32.
FleseriuMYedinakCCampbellC. Significant headache improvement after transsphenoidal surgery in patients with small sellar lesions. J Neurosurg2009; 110: 354–358.
33.
MaFYAndersonGMGunnTD. Prolactin specifically activates signal transducer and activator of transcription 5b in neuroendocrine dopaminergic neurons. Endocrinology2005; 146: 5112–5119.
34.
SilbersteinSD. Sex hormones and headache. Rev Neurol (Paris)2000; 156(Suppl 4): 4S30–4S41.
35.
MasciaAAfraJSchoenenJ. Dopamine and migraine: A review of pharmacological, biochemical, neurophysiological, and therapeutic data. Cephalalgia1998; 18: 174–182.
36.
MatharuMMayA. Functional and structural neuroimaging in trigeminal autonomic cephalalgias. Curr Pain Headache Rep2008; 12: 132–137.
37.
SchankinCJReifferscheidAKKrumbholzM. Headache in patients with pituitary adenoma: Clinical and paraclinical findings. Cephalalgia2012; 32: 1198–1207.
38.
ColaoADi SarnoALandiML. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab1997; 82: 3574–3579.
39.
HoskinKLKaubeHGoadsbyPJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain1996; 119(Pt 1): 249–256.
40.
MalickAStrassmanRMBursteinR. Trigeminohypothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat. J Neurophysiol2000; 84: 2078–2112.
41.
ViisanenHAnsahOBPertovaaraA. The role of the dopamine D2 receptor in descending control of pain induced by motor cortex stimulation in the neuropathic rat. Brain Res Bull2012; 89: 133–143.
42.
JensenTSYakshTL. Effects of an intrathecal dopamine agonist, apomorphine, on thermal and chemical evoked noxious responses in rats. Brain Res1984; 296: 285–293.
43.
HagelbergNJaaskelainenSKMartikainenIK. Striatal dopamine D2 receptors in modulation of pain in humans: A review. Eur J Pharmacol2004; 500: 187–192.
44.
LarnerAJ. Headache induced by dopamine agonists prescribed for prolactinoma: Think SUNCT!. Int J Clin Pract2006; 60: 360–361.
